CASIRIVIMAB\IMDEVIMAB vs CASPOFUNGIN: Which Drug Is Safer?
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
CASIRIVIMAB\IMDEVIMAB vs CASPOFUNGIN: Safety Overview
| Metric | CASIRIVIMAB\IMDEVIMAB | CASPOFUNGIN |
|---|---|---|
| Total FAERS Reports | 4,248 | 3,814 |
| Deaths Reported | 137 | 1,419 |
| Death Rate | 3.2% | 37.2% |
| Hospitalizations | 1,351 | 1,638 |
| Average Patient Age | 54.3 yrs | 47.5 yrs |
| % Female Patients | 55.4% | 42.8% |
| FDA Approval Date | N/A | Dec 30, 2016 |
| Manufacturer | N/A | Sandoz Inc |
| Route | N/A | INTRAVENOUS |
| Marketing Status | N/A | Discontinued |